Evolution, Not Revolution, Marks Progress In Targeted Oncology Therapy – AACR

The American Association for Cancer Research’s second annual Cancer Progress Report makes the case that oncology progression is more a process of refinement than breakthrough right now.

Though targeted oncology is still a booming sector, growth in the field is being driven less by revolutionary new approaches than by evolutionary or incremental improvements in targeting, sequencing and combining the new cancer drugs, according to a new report by the American Association for Cancer Research. But those gains are helping to shrink development and FDA review times in oncology.

Oncology drugs are currently experiencing a boom in approvals

More from Clinical Trials

More from R&D